Hansa Biopharma – Deep Dive into other indications for Imlifidase

Meet and ask questions to Hansa Biopharma’s Elisabeth Sonesson, Global Franchise Lead Autoimmune diseases – Tuesday the 30th of May at 2.00 PM CEST.

In this event, we will dive into the autoimmune disease space, where Hansa’s antibody-cleaving enzyme, imlifidase may potentially be relevant to stop an acute immunologic attack on organs forced by the body’s own immune system. Hansa has demonstrated very encouraging outcome in phase 2 program in anti-GBM disease and has recently completed enrollment in a phase 2 program investigating another acute autoimmune disease, namely Guillain-Barré syndrome (GBS). Lastly, Elisabeth will also cover Hansa’s AMR study post transplantation in phase 2, where topline data recently demonstrated statistical superiority over plasma exchange in the five days following the start of the treatment.

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving, and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, enabling kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program based on the company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy, and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA.

Disclaimer: HC Andersen Capital receives payment from Hansa Biopharma for a DigitalIR/Corporate Visibility agreement. Claus Thestrup 14:25 CEST – 11/05/2023.